Corona Remedies reported a 21.75% increase in consolidated net profit to Rs 52.32 crore for Q2 FY26, with revenue from operations rising 15.05% to Rs 361.13 crore compared to Q2 FY25. For the half-year ended FY26, net profit grew 35.10% to Rs 98.52 crore on a 16.92% revenue increase. The company attributes its strong performance to strategic consistency, disciplined execution, and focus on core therapeutic segments.